MACITENTAN | N204410 | ACTELION PHARMACEUTICALS US INC
| Trial # | Patent | Type | Petitioner | Status | Filed | Decision |
|---|---|---|---|---|---|---|
| IPR2025-01139 | 8268847 | IPR | United Therapeutics Corporation | Discretionary Denial | 2025-06-10 | 2025-11-20 |
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
ACTELION PHARMACEUTICALS LTD et al v. SEASONS BIOTECHNOLOGY (TAIZHOU) CO. LTD. et al 2 patentsANDA 211026macitentan | D.N.J. | 2025-08-28 | Terminated 2025-10-21 | — |
Actelion Pharmaceuticals Ltd. et al v. Mylan Pharmaceuticals Inc. 2 patentsANDA 211161macitentan | WVND | 2023-11-07 | Terminated 2024-09-20 | — |
| D.N.J. | 2020-10-05 | Terminated 2021-01-22 | — | |
ACTELION PHARMACEUTICALS LTD v. AUROBINDO PHARMA USA INC. et al 1 patentANDA 211198macitentan | D.N.J. | 2019-07-16 | Terminated 2020-07-15 | — |
ACTELION PHARMACEUTICALS LTD v. ZYDUS PHARMACEUTICALS (USA) INC. et al 1 patentANDA 211224, 211000macitentan | D.N.J. | 2018-01-31 | Terminated 2020-09-22 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Code | Date | Status |
|---|---|---|
| M-187 | Feb 28, 2028 | Active |
| PED | Aug 28, 2028 | Active |